Der Kaninchen Polyklonal Anti-FERMT3-Antikörper wurde für WB und ELISA validiert. Er ist geeignet, FERMT3 in Proben von Human, Maus und Ratte zu detektieren.
Produktnummer ABIN6990977
Kurzübersicht für FERMT3 Antikörper (C-Term) (ABIN6990977)
KINDLIN3 Antibody is affinity chromatography purified via peptide column.
Immunogen
KINDLIN3 antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of the human KINDLIN3. The immunogen is located within the last 50 amino acids of KINDLIN3.
FERMT3
Reaktivität: Human
Wirt: Kaninchen
Polyclonal
FITC
Applikationshinweise
KINDLIN3 antibody can be used for detection of KINDLIN3 by Western blot at 1 and 2 μ,g/mL.
Antibody validated: Western Blot in rat samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
KINDLIN3 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
KINDLIN3 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
FERMT3
(Fermitin Family Member 3 (FERMT3))
Andere Bezeichnung
KINDLIN3
Hintergrund
KINDLIN3 Antibody: The three KINDLINs are a novel family of focal adhesion proteins, localizing to integrin adhesion sites. The KINDLIN proteins are composed of a centrally located FERM domain interrupted by a pleckstrin homology (PH) domain. KINDLIN1 and KINDLIN2 have been shown to play an essential role in integrin-mediated adhesion and spreading. In contrast to the widely expressed KINDLIN1 and KINDLIN2, KINDLIN3 is restricted to hematopoietic cells and is particularly abundant in megakaryocytes and platelets. Several reports describe a transcriptional misregulation of KINDLINs in various types of cancer. A recent study demonstrates that KINDLIN3 is essential for platelet integrin activation and subsequent integrin outside-in signaling, suggesting it may serve as a potential target for the design of therapeutics aimed at specifically disrupting integrin activation in platelets and leukocytes.